Pregnancy-Associated Plasma Protein A (PAPP-A) and Preeclampsia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10287234" target="_blank" >RIV/00216208:11110/14:10287234 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10287234

Výsledek na webu

<a href="http://dx.doi.org/10.1016/B978-0-12-800094-6.00005-4" target="_blank" >http://dx.doi.org/10.1016/B978-0-12-800094-6.00005-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-12-800094-6.00005-4" target="_blank" >10.1016/B978-0-12-800094-6.00005-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pregnancy-Associated Plasma Protein A (PAPP-A) and Preeclampsia

Popis výsledku v původním jazyce

Pregnancy-associated plasma protein A (PAPP-A) is a key regulator of insulin-like growth factor bioavailability essential for normal fetal development. In maternal blood, this protein increases with gestational age and then rapidly decreases after delivery. It is routinely used for Down syndrome screening in the first trimester of pregnancy, and its decrease compared to a normal pregnancy indicates an increased risk for both chromosomal anomalies and adverse pregnancy outcomes. It belongs to a group ofbiomarkers that predict later preeclampsia development, primarily early onset preeclampsia; however, it should be combined with a Doppler ultrasonography of the uterine artery (pulsatile index) and other biochemical and maternal factors to achieve a higher detection rate with an acceptable false positivity rate. Some studies have demonstrated an even more pronounced decrease of PAPP-A in the early second trimester of pregnancy in women who subsequently develop preeclampsia compared with

Název v anglickém jazyce

Pregnancy-Associated Plasma Protein A (PAPP-A) and Preeclampsia

Popis výsledku anglicky

Pregnancy-associated plasma protein A (PAPP-A) is a key regulator of insulin-like growth factor bioavailability essential for normal fetal development. In maternal blood, this protein increases with gestational age and then rapidly decreases after delivery. It is routinely used for Down syndrome screening in the first trimester of pregnancy, and its decrease compared to a normal pregnancy indicates an increased risk for both chromosomal anomalies and adverse pregnancy outcomes. It belongs to a group ofbiomarkers that predict later preeclampsia development, primarily early onset preeclampsia; however, it should be combined with a Doppler ultrasonography of the uterine artery (pulsatile index) and other biochemical and maternal factors to achieve a higher detection rate with an acceptable false positivity rate. Some studies have demonstrated an even more pronounced decrease of PAPP-A in the early second trimester of pregnancy in women who subsequently develop preeclampsia compared with

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Advances in Clinical Chemistry

ISSN

0065-2423

e-ISSN

—

Svazek periodika

63

Číslo periodika v rámci svazku

-

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

41

Strana od-do

169-209

Kód UT WoS článku

000331015900005

EID výsledku v databázi Scopus

—